Haruko K Shimoda

Learn More
Ten-Eleven-Translocation 2 (TET2) is an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) and thereby alters the epigenetic state of DNA; somatic loss-of-function mutations of TET2 are frequently observed in patients with diverse myeloid malignancies. To study the function of TET2 in vivo, we analyzed Ayu17-449(More)
The acquired JAK2 V617F mutation is observed in the majority of patients with BCR-ABL1 negative chronic myeloproliferative neoplasms (MPN). BCR-ABL1 negative MPN displays myeloproliferation with an elevated leucocyte alkaline phosphatase (LAP) activity, a neutrophil activation marker. We tried to separate the downstream signalling of JAK2 V617F to stimulate(More)
Yoko Kubuki, M.D., Kotaro Shide, M.D., Takuro Kameda, M.D., Takumi Yamaji, M.D., Masaaki Sekine, M.D., Ayako Kamiunten, M.D., Keiichi Akizuki, M.D., Haruko Shimoda, M.D., Yuki Tahira, M.D., Kenichi Nakamura, M.D., Hiroo Abe, M.D., Tadashi Miike, M.D., Hisayoshi Iwakiri, M.D., Yoshihiro Tahara, M.D., Mitsue Sueta, M.D., Kanna Hashimoto, M.D., Shojiro(More)
An acquired JAK2 V617F mutation is found in most patients with polycythemia vera (PV), and about half of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Mice transplanted with bone marrow cells in which JAK2 V617F was retrovirally expressed developed PV-like features, but not ET or PMF. To address the contribution of this(More)
Acute myelogenous leukemia (AML) cells are generally hemosensitive, and 70–80% of AML patients undergo complete emission after chemotherapy [1]. However, long-term diseaseree survival remains as low as 30–50% [1], mainly because of elapse after chemotherapy. The relapse has been ascribed to minmal residual disease (MRD) in the bone marrow (BM) [2]. It has(More)
The activating mutations in JAK2 (including JAK2V617F) that have been described in patients with myeloproliferative neoplasms (MPNs) are linked directly to MPN pathogenesis. We developed R723, an orally bioavailable small molecule that inhibits JAK2 activity in vitro by 50% at a concentration of 2nM, while having minimal effects on JAK3, TYK2, and JAK1(More)
Fibronectin (FN) plays important roles in the proliferation, differentiation, and maintenance of megakaryocytic-lineage cells through FN receptors. However, substantial role of FN receptors and their functional assignment in proplatelet-like formation (PPF) of megakaryocytes are not yet fully understood. Herein, we investigated the effects of FN receptors(More)
Secondary central nervous system lymphoma (SCNSL) without extra-central nervous system (CNS) involvement is characterized by isolated secondary CNS relapse in malignant lymphoma patients. SCNSL is a rare disease, and no standard treatment has yet been established. To elucidate the clinical characteristics and outcomes of SCNSL, we retrospectively analyzed(More)
We previously reported that mice transgenic (Tg) for thrombopoietin (TPO) developed progressive fibrosis and osteosclerosis of the bone marrow. Here, we show that TPO-overexpressing mice also exhibited notable histological changes in the kidneys, including an increased number of mesangial cells, expansion of the mesangial matrix in the glomerulus, and(More)
OBJECTIVE The efficacy of mogamulizumab in adult T-cell leukemia/lymphoma (ATLL) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real-life settings have demonstrated worse outcomes. METHOD We retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab(More)